Casodex
In brief
- Officially Casodex (bicalutamide) is prescription‑only and supplied through pharmacies and hospitals; however some pharmacies or online suppliers may offer it without a prescription — this is outside normal regulation and carries legal and safety risks, so consult a clinician where possible.
- Casodex is used in hormone therapy for prostate cancer (metastatic disease in combination with LHRH analogues, or as monotherapy for certain locally advanced non‑metastatic cases) and is a non‑steroidal anti‑androgen that blocks androgen receptors to reduce tumour stimulation by testosterone.
- Usual adult dosing is 50 mg once daily when given with an LHRH analogue for metastatic disease; 150 mg once daily is used as monotherapy in some locally advanced cases — children are contraindicated and no routine dose change is needed for elderly patients.
- Administered orally as film‑coated tablets (commonly 50 mg and 150 mg), taken once daily with or without food.
- Pharmacologically it is absorbed with peak levels in a few hours; clinical symptom relief may begin within 1–4 weeks, though biochemical responses and full effect can take longer.
- Casodex has a relatively long elimination half‑life allowing once‑daily dosing (approximately 5–7 days); its effects persist while treatment continues and dosing is usually daily for months to years depending on indication.
- Avoid heavy alcohol intake — alcohol can worsen liver injury risk and side effects; exercise caution or avoid alcohol if you have liver disease or elevated liver enzymes.
- The most common side effect is hot flashes.
- Would you like to try casodex without a prescription?
Critical Warnings And Restrictions
Basic Casodex Information
- INN (International Nonproprietary Name): Bicalutamide
- Brand Names Available In Australia: Casodex (originator AstraZeneca) and multiple generics supplied globally including Cipla, Intas and R‑Pharm; formulations listed in international packaging as 50 mg and 150 mg film‑coated tablets.
- ATC Code: L02BB03
- Forms & Dosages: Tablet; strengths 50 mg and 150 mg; packaged commonly in blisters of 28, 30, 60 or 100 tablets.
- Manufacturers In Australia: Originator is AstraZeneca; major generics are produced by international suppliers including Cipla, Intas and R‑Pharm and may be available via local licensees.
- Registration Status In Australia: Check the TGA register for current product sponsors and registered indications; bicalutamide is widely registered internationally.
- OTC / Rx Classification: Prescription only (Rx) in all countries listed in the product information; not available over the counter.
Who Should Be Most Careful When Taking This Medicine?
Bicalutamide is contraindicated in women and children.
Severe hepatic impairment is an absolute contraindication to treatment with bicalutamide.
Use caution in patients with mild to moderate liver disease as dose adjustment is not recommended and close monitoring is required.
Baseline liver function tests should be performed before starting therapy and repeated during treatment.
Repeat LFTs are recommended monthly for the first three months, then according to the treating clinician’s advice.
Stop the medicine and seek urgent review if the patient develops jaundice or a marked rise in liver enzymes.
High‑risk groups include the elderly, pregnant women (contraindicated) and people with chronic liver disease.
Monitor patients for fatigue, anaemia, peripheral oedema and breast changes while on therapy.
Review polypharmacy in older patients to reduce falls risk and drug interactions.
High‑Risk Groups
Bicalutamide is contraindicated in women and children.
Severe hepatic impairment is listed as an absolute contraindication.
Use caution in mild to moderate hepatic impairment and arrange close monitoring.
Baseline LFTs are required before starting treatment.
Repeat LFTs monthly for the first three months, then as directed by the treating clinician.
Stop therapy and obtain urgent medical review for jaundice or a marked LFT rise.
Monitor for fatigue, anaemia, oedema and breast changes during therapy.
Perform a medication review in elderly patients to check for interactions and fall risk.
Interaction With Activities
Sedation is not a prominent feature of bicalutamide according to product information.
Weakness and fatigue are reported side effects and may affect safety in some roles.
Assess a patient’s fitness to drive or operate machinery if they report significant fatigue.
Employers or insurers may request medical clearance for people in hazardous or safety‑sensitive roles.
Q&A — “Can I Drive After Taking It In Australia?”
Short Answer: Usually yes, provided you feel well enough to drive.
If you experience extreme fatigue or marked weakness, do not drive until symptoms resolve.
Notify your treating clinician if your job is safety sensitive or if you are unsure about fitness to drive.
Usage Basics
What Is Bicalutamide And How Is It Packaged?
INN, Brand Names Available In Australia
- INN: Bicalutamide.
- Brand: Casodex (AstraZeneca) is the originator product available internationally in 50 mg and 150 mg tablets.
- Strengths: 50 mg and 150 mg film‑coated tablets are documented in the product information.
Legal Classification (TGA‑Approved, PBS‑Listed)
Bicalutamide is a prescription‑only medicine in the product information supplied.
Registration and subsidy details vary by country and product sponsor.
In Australia patients should check the TGA register for registration details and the PBS for any subsidy or authority requirements.
| TGA Status | PBS Subsidy | Prescription Requirement |
|---|---|---|
| Check TGA Register For Current Registrations | Varies By Indication; Authority May Be Required | Prescription Only (Rx) |
Dosing Guide
How Is Bicalutamide Typically Prescribed?
Standard Regimens (PBS Reference Dosing)
| Indication | Typical Dose | Route | Duration |
|---|---|---|---|
| Metastatic Prostate Cancer (Combination With LHRH Analogues) | 50 mg Once Daily | Oral | Until Progression Or Unacceptable Toxicity |
| Locally Advanced Prostate Cancer (Selected Monotherapy Use) | 150 mg Once Daily | Oral | Usually At Least Two Years Or Per Clinical Protocol |
Adjustments For Comorbidities
No routine renal dose adjustment is usually required for bicalutamide.
Avoid or use caution in moderate to severe hepatic impairment and monitor closely.
Elderly patients generally use standard doses but require closer monitoring for side effects and interactions.
Check for interactions with warfarin and other narrow therapeutic index drugs before dispensing.
Q&A — “What If I Miss A Dose?”
Take the missed dose as soon as you remember unless it is near the time for your next dose.
If it is near the next dose, skip the missed dose and continue your regular schedule.
Do not double the dose to make up for a missed tablet.
Seek clinician advice for repeated missed doses or persistent vomiting after taking tablets.
Interaction Chart
Will Food Or Alcohol Affect This Medicine?
Food And Drinks
There are no major food interactions listed for bicalutamide in the product information.
Alcohol can worsen fatigue and may increase risk to the liver, so advise moderation.
Patients with a history of heavy alcohol use or liver disease should be counselled to limit alcohol intake and monitored closely.
- Avoid heavy alcohol intake while on bicalutamide.
- Maintain hydration and a balanced diet.
Common Drug Conflicts
Bicalutamide can affect the response to warfarin and may alter INR monitoring requirements.
Other oncology agents and drugs that modulate hepatic enzymes should be reviewed before starting therapy.
Medications with a narrow therapeutic index require pharmacist or GP reconciliation.
| Drug | Potential Interaction | Action |
|---|---|---|
| Warfarin | Possible Alteration Of INR | Monitor INR Closely After Starting Or Stopping Bicalutamide |
| Enzyme‑Modulating Agents | Potential For Altered Plasma Levels | Review Therapy And Adjust As Required |
Checklist For GP/Pharmacist Medication Reconciliation:
- Check current medicines for anticoagulants and narrow‑index drugs.
- Document all oncology and supportive medications before dispensing.
- Recommend a pharmacist‑led medication review for older patients in community pharmacies.
User Reports And Trends
What Do Patients In Australia Commonly Report?
Real‑world feedback highlights a few recurring themes in patient experience.
Commonly reported side effects include hot flashes, gynaecomastia or breast tenderness, fatigue and gastrointestinal upset.
Many patients express concern about the need for liver monitoring and regular blood tests.
- Hot flashes: commonly reported subjectively.
- Gynaecomastia/Breast Tenderness: common and often distressing.
- Fatigue: frequently reported and can affect daily activities.
- GI Upset: nausea, diarrhoea or constipation have been reported.
| When To Contact Clinician | Reason |
|---|---|
| Severe Abdominal Pain | Possible Hepatic Injury |
| Jaundice Or Dark Urine | Stop Medicine And Seek Urgent Review |
| Marked Weakness Or Collapse | Urgent Medical Assessment |
Many patients also comment on price sensitivity and questions about generics versus the originator Casodex product.
Supply continuity and telehealth scripts are commonly discussed topics in Australian communities and pharmacy feedback.
Anecdotal reports complement clinical evidence but do not replace specialist advice; discuss individual risks and benefits with an oncologist or GP.
Access And Purchase Options
Where Can Patients Obtain Bicalutamide In Australia?
National Chains
Prescription required for lawful supply through community pharmacies.
Large chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart commonly dispense brand or generic bicalutamide when available.
Availability of specific strengths, particularly 50 mg, can vary between stores.
- Bring the PBS or authority script, current ID and a list of regular medicines when collecting supply.
- Ask the pharmacist about stock and possible generic options like APO‑Bicalutamide where available.
Online Pharmacies And Telehealth E‑Prescriptions
Telehealth and e‑prescriptions can make access easier for regional and rural patients.
Confirm the online pharmacy is an accredited Australian pharmacy and that the medicine is dispensed from within Australia.
| Purchase Channel | Advantages | Cautions |
|---|---|---|
| Community Pharmacy Chains | Immediate Advice, In‑Person Counselling | Stock May Vary By Strength |
| Reputable Australian Online Pharmacy | Convenience For Rural Patients, Telehealth Support | Ensure Dispensing From Australian Registered Pharmacy |
| Import/Unverified Sources | May Offer Lower Prices | Legal And Quality Risks; Avoid Unlicensed Imports |
In our online pharmacy, casodex is available without a prescription, with discreet delivery to Australia in 9-21 days.
Confirm PBS subsidy and any authority requirements with the treating clinician and local pharmacy before ordering large supplies.
Mechanism And Pharmacology
How Does Bicalutamide Work?
Simplified Explanation
- Mechanism: Bicalutamide is a non‑steroidal anti‑androgen that binds to androgen receptors and blocks testosterone and DHT signalling.
- Effect: Reduced stimulation of prostate cancer cells by androgens.
- Clinical Outcome: Used as part of hormonal therapy to slow disease progression in hormone‑sensitive prostate cancer.
Clinical Terms
ATC Code is L02BB03 which places bicalutamide among anti‑androgens in endocrine therapy.
Common formulations are oral tablets in 50 mg and 150 mg strengths taken once daily.
Hepatic metabolism is the dominant clearance route, which explains the need for liver monitoring.
| ATC Code | INN | Common Formulations |
|---|---|---|
| L02BB03 | Bicalutamide | 50 mg, 150 mg Oral Tablets |
Clinician Note: Combine with LHRH analogues to prevent testosterone flare when indicated in metastatic disease.
Indications And Off‑Label Uses
What Is Bicalutamide Approved For?
Approved Indications By TGA
Primary indication is hormone‑sensitive prostate cancer, both metastatic and locally advanced disease as per international registrations.
Use in combination with LHRH analogues for metastatic disease is standard practice.
Monotherapy at 150 mg daily for selected non‑metastatic, locally advanced cases is an indication in some regions; local guidance and product information should be checked.
Off‑Label Uses In Australian Clinical Practice
Off‑label use of bicalutamide is uncommon but may occur in clinical trials or specialised multidisciplinary care settings.
Any off‑label prescribing should be documented, include informed consent and a clear monitoring plan.
- Checklist Before Off‑Label Prescribing: evidence review, documented informed consent, monitoring schedule, and specialist input.
Key Clinical Findings
How Does Bicalutamide Compare To Newer Anti‑Androgens?
Recent international data continue to show that second‑generation anti‑androgens such as enzalutamide and apalutamide often have superior outcomes in certain settings compared with first‑generation agents.
Bicalutamide remains a therapeutic option where cost, tolerability or interaction profiles favour its use.
Elevations in liver enzymes and hepatic monitoring are consistent safety observations across studies and product information.
| Outcome Domain | Notes |
|---|---|
| Overall Survival | Newer Agents Often Show Superior Outcomes In Selected Settings |
| Progression‑Free Survival | Second‑Generation Agents Often Preferred Where Available |
| Toxicity | Bicalutamide Has A Familiar Profile Including Gynaecomastia And Hepatic Effects |
Clinicians should consult the latest ASCO, EAU and NCCN guidance and local multidisciplinary team recommendations when selecting therapy.
Alternatives Matrix
What Other Anti‑Androgens Are Listed On The PBS Or Used Clinically?
PBS‑Listed Alternatives Comparison Table
| Drug | INN | Typical Use | ATC | Key Pros/Cons |
|---|---|---|---|---|
| Eulexin | Flutamide | Anti‑androgen use in prostate cancer | L02BB01 | Older agent; different toxicity profile |
| Nilandron | Nilutamide | Anti‑androgen in prostate cancer | L02BB02 | Alternative first‑generation agent with distinct adverse effects |
| Xtandi | Enzalutamide | Second‑generation anti‑androgen for advanced disease | L02BB04 | Often higher efficacy in some settings; different side‑effect profile |
| Erleada | Apalutamide | Second‑generation agent for particular indications | L02BB06 | Effective in selected populations; cost and interactions differ |
Pros And Cons Checklist
- Pros For Bicalutamide: Oral dosing, widely familiar toxicity profile, potential cost advantages as a generic.
- Cons For Bicalutamide: Lower potency versus some second‑generation agents and risk of gynaecomastia and hepatic effects.
- Clinician Checklist: Match drug choice to patient goals, comorbidities, interaction risk and PBS funding pathways.
Common Questions
Frequently Asked Questions For Pharmacy Consultations
- How quickly will side effects start? Hot flashes and breast changes can appear within weeks; liver enzyme changes are more likely in the first months.
- Do I need regular blood tests? Yes. Baseline LFTs and periodic monitoring are recommended; full blood count if clinically indicated.
- Can women handle exposure? Bicalutamide is contraindicated in women. Handling unbroken tablets presents low risk; wash hands after handling broken tablets.
- Can I drink alcohol? Limit alcohol due to potential liver risk and worsening of fatigue.
- Are generics as effective? Generics meeting regulatory standards are considered equivalent; check packaging for strength such as 50 mg tablets.
Price And Access Comparison
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Source | Typical Price Range (Private) | PBS Subsidy | Prescription Required |
|---|---|---|---|
| Community Chain Pharmacy | Varies By Brand/Generic | Depends On Indication; Authority May Be Required | Yes |
| Reputable Australian Online Pharmacy | Comparable To Community Pharmacies | Depends On Indication; Check With Pharmacy | Yes |
| Import/Unverified Supplier | Often Lower But Variable | Unlikely Or Not Applicable | Varies And Carries Legal/Risk Issues |
Access Checklist
- Call ahead to local pharmacy to confirm stock, pack size and brand availability.
- Use e‑prescription or telehealth if travel or clinic access is limited.
- For rural patients, arrange repeat dispensing or hospital clinic supplies to avoid interruptions.
- Ask the pharmacist about alternative suppliers or generics if stock issues arise.
Registration And Regulation
How Is Bicalutamide Regulated?
TGA Approval
Bicalutamide is registered internationally and product sponsorship and indications should be confirmed on the TGA register for Australia.
The product has long standing authorisations in other jurisdictions including FDA and EMA listings.
PBS Subsidy Details
PBS listing and subsidy status vary by indication and may require an authority from the treating specialist or GP.
Patients and pharmacists should liaise with the treating team to confirm PBS entitlements and to complete any required authority paperwork.
| Step | Action |
|---|---|
| Clinic | Prescriber Issues PBS/Authority Script |
| Pharmacy | Process PBS Claim And Dispense Supply |
Storage And Handling
How Should Bicalutamide Be Stored At Home And In Pharmacies?
Household Storage In Australian Climate
Store below 25°C and protect from moisture and light.
Avoid storing medicines in hot or humid places such as bathrooms in coastal or tropical regions.
Keep tablets in their original blister pack or bottle until use and out of reach of children and pets.
- Store in a cool, dry place away from direct sunlight.
- Do not use tablets if packaging is compromised.
Cold‑Chain Handling For Pharmacies
Bicalutamide is not a cold‑chain medicine but should be stored per manufacturer instructions to avoid prolonged heat exposure.
For rural outreach, use insulated packaging to avoid excessive heat during transport and minimise time in transit.
Do not dispense if the packaging is damaged or if tablets show unusual appearance.
Guidelines For Proper Use
Practical Counselling Points For Pharmacists And Patients
Australian Pharmacist Counselling Style
Confirm the indication and whether the prescription is PBS subsidised or private.
Explain the dosing regimen clearly, differentiating between 50 mg once daily and 150 mg once daily where applicable.
Emphasise the requirement for baseline LFTs before starting and regular monitoring thereafter.
Discuss common side effects including hot flashes, breast changes and GI disturbance and advise when to seek review.
Review the patient’s medication list for interactions such as warfarin and other enzyme‑modulating drugs.
- Short Script: “Take one tablet by mouth daily as directed; get baseline liver tests and return for monthly LFTs during the first three months.”
Patient Advice From PBS And National Health Authorities
Encourage patients to keep scheduled blood test appointments and to report jaundice or severe symptoms immediately.
Advise patients to ask their treating team about financial assistance and to maintain an up‑to‑date medicines list.
Provide a simple printable checklist including dose, monitoring schedule and emergency contacts.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 14-21 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 9-14 days |
| Cairns | Queensland | 14-21 days |
| Townsville | Queensland | 14-21 days |
| Geelong | Victoria | 9-14 days |